The Genetic and Neurobiological Studies section of the Huntington's Disease Research Center examines patterns of disease expression with the goal of identifying disease modifying mechanisms which may be invoked for treatment of the illness. The four proposed projects are; 1. Variation in clinical expression. We propose investigations in three areas to evaluate the effects of modifying factors upon disease expression: (a) We propose to examine the relationship of repeat size to disease expression including the onset age and rate of progression. (b) We propose to study factors contributing to the variation in disease expression other than the trinucleotide repeat. (c) We propose to examine factors associated with large intergenerational expansion of the expanded CAG repeat. By defining these modifiers, more accurate estimates of the expected disease course and onset can be made, and will permit assessment of change from the expected disease course in clinical trials. 2. CAG repeat expansion from intermediate to clinical range. We reported the overlap between the intermediate (32 to 38 repeats) and the clinical range of 37 repeats in families with de novo expressions of HD. These studies suggest that repeat size atone is not sufficient for HD expression. We propose to study patterns of repeat stability in our existing sample of de novo expression families as well as newly identified families. We will compare the stability of this repeat among progeny of male versus female members of the family in multiple generations for biologic mechanisms influencing repeat stability. The genetic risks associated with intermediate repeats are unknown and this has created ambiguities in genetic testing. 3. Brain Studies. Our past brain studies have generated two competing hypotheses; (a) either the HD gene interferes with early cortical and subcortical development, or (b) the gene's effects accrue gradually in mid-life in a normally developed central nervous system (CNS). Our recent studies of brain specimens of HD gene carriers dying before onset of disease found increased oligodendrocyte densities in the tail of the caudate nucleus suggesting early CNS development abnormalities. We propose to expand the number of presymptomatic HD cases studied and to examine regions afflicted only in later stages of disease as well as regions of white matter. We hypothesize that cell density abnormalities will be observed throughout he presymptomatic HD brain. 4). Collection of fetal tissues of HD gene carriers. We propose to collect fetal brain, testes and ovaries, and other tissues to be made available to HD center and other investigators. One of the largest predictive and prenatal testing programs in the nation is affiliated with our HD center and we estimate 2 to 5 prenatal tests per year in this program. Until now no systematic program for collection of fetal tissues from across the nation has existed. We propose therefore to establish a network among HD testing facilities nationwide to coordinate the collection of fetal tissues.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Specialized Center (P50)
Project #
5P50NS016367-20
Application #
6112149
Study Section
Project Start
1999-07-01
Project End
2000-06-30
Budget Start
1998-10-01
Budget End
1999-09-30
Support Year
20
Fiscal Year
1999
Total Cost
Indirect Cost
Name
Massachusetts General Hospital
Department
Type
DUNS #
City
Boston
State
MA
Country
United States
Zip Code
02199
Lee, Jong-Min; Chao, Michael J; Harold, Denise et al. (2017) A modifier of Huntington's disease onset at the MLH1 locus. Hum Mol Genet 26:3859-3867
HD iPSC Consortium (2017) Developmental alterations in Huntington's disease neural cells and pharmacological rescue in cells and mice. Nat Neurosci 20:648-660
Chao, Michael J; Gillis, Tammy; Atwal, Ranjit S et al. (2017) Haplotype-based stratification of Huntington's disease. Eur J Hum Genet 25:1202-1209
Shin, Aram; Shin, Baehyun; Shin, Jun Wan et al. (2017) Novel allele-specific quantification methods reveal no effects of adult onset CAG repeats on HTT mRNA and protein levels. Hum Mol Genet 26:1258-1267
Keum, Jae Whan; Shin, Aram; Gillis, Tammy et al. (2016) The HTT CAG-Expansion Mutation Determines Age at Death but Not Disease Duration in Huntington Disease. Am J Hum Genet 98:287-98
Correia, Kevin; Harold, Denise; Kim, Kyung-Hee et al. (2015) The Genetic Modifiers of Motor OnsetAge (GeM MOA) Website: Genome-wide Association Analysis for Genetic Modifiers of Huntington's Disease. J Huntingtons Dis 4:279-84
Lee, Jong-Min; Kim, Kyung-Hee; Shin, Aram et al. (2015) Sequence-Level Analysis of the Major European Huntington Disease Haplotype. Am J Hum Genet 97:435-44
Ramos, Eliana Marisa; Gillis, Tammy; Mysore, Jayalakshmi S et al. (2015) Haplotype analysis of the 4p16.3 region in Portuguese families with Huntington's disease. Am J Med Genet B Neuropsychiatr Genet 168B:135-43
Genetic Modifiers of Huntington’s Disease (GeM-HD) Consortium (2015) Identification of Genetic Factors that Modify Clinical Onset of Huntington's Disease. Cell 162:516-26
Biagioli, Marta; Ferrari, Francesco; Mendenhall, Eric M et al. (2015) Htt CAG repeat expansion confers pleiotropic gains of mutant huntingtin function in chromatin regulation. Hum Mol Genet 24:2442-57

Showing the most recent 10 out of 42 publications